Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy

The purpose of this study is to evaluate the pharmacodynamics, safety, and tolerability of DT-168 Ophthalmic Solution in pre-keratoplasty patients with Fuchs endothelial corneal dystrophy.

Participants needed: 28
Trial details
Phase: Phase 2Age: 30+Biological sex: AllType: InterventionalSponsor: Design Therapeutics, Inc.Updated: Dec 29, 2025Locations: 2
Eligibility criteria

Participant is scheduled to undergo a keratoplasty for management of FECD indepe... [+4]

Any ocular or medical condition in the study eligible eye which is clinically si... [+9]

Read more
Status: Recruiting

A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's Ataxia

The purpose of this study is to evaluate the safety and tolerability, and pharmacokinetics of DT-216P2 administered multiple ascending doses in patients with FA.

Participants needed: 20
Trial details
Phase: Phase 1, Phase 2Age: 18-65Biological sex: AllType: InterventionalSponsor: Design Therapeutics, Inc.Updated: May 18, 2025Locations: 3
Eligibility criteria

Participants must be 18-65 years of age inclusive, at the time of signing the in... [+5]

Any concomitant medical condition that in the opinion of the investigator, puts... [+3]

Read more
Status: Not yet recruiting

A Single Ascending Dose Study of DT-216P2 in Normal Healthy Participants

This purpose of the study is to evaluate the safety, tolerability and pharmacokinetics of single ascending doses of DT-216P2 administered either subcutaneously (SC) and intravenously (IV) in normal healthy participants. Approximately 36 participants will be enrolled into this study.

Participants needed: 36
Trial details
Phase: Phase 1Age: 18-45Biological sex: AllType: InterventionalSponsor: Design Therapeutics, Inc.Updated: Feb 21, 2025Locations: 1
Eligibility criteria

Participants must be 18-45 years of age inclusive, at the time of signing the in... [+5]

Any concomitant medical condition that in the opinion of the investigator, puts... [+2]

Read more